Candel Therapeutics (CADL)
(Delayed Data from NSDQ)
$6.70 USD
+0.19 (2.92%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $6.72 +0.02 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Candel Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -37.94 | -18.79 | -36.12 | -17.68 | NA |
Depreciation/Amortization & Depletion | 0.96 | 0.78 | 0.23 | 0.09 | NA |
Net Change from Assets/Liabilities | -0.53 | 0.07 | -0.88 | 1.77 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 3.26 | -13.47 | 14.55 | 6.74 | NA |
Net Cash From Operating Activities | -34.24 | -31.42 | -22.22 | -9.07 | NA |
Property & Equipment | -0.28 | -1.30 | -1.84 | -1.48 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 0.00 | 0.00 | 0.00 | 39.93 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -0.28 | -1.30 | -1.84 | 38.46 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.06 | 71.80 | 0.03 | NA |
Issuance (Repayment) of Debt | 0.00 | 19.91 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.46 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -0.12 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | -0.12 | 19.97 | 71.80 | 0.49 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -34.65 | -12.74 | 47.75 | 29.87 | NA |
Cash at Beginning of Period | 70.32 | 83.07 | 35.32 | 5.45 | NA |
Cash at End of Period | 35.68 | 70.32 | 83.07 | 35.32 | NA |
Diluted Net EPS | -1.31 | -0.65 | -1.91 | NA | NA |
Fiscal Year End for Candel Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -8.22 | -37.94 | -26.84 | -18.41 |
Depreciation/Amortization & Depletion | NA | 0.25 | 0.96 | 0.71 | 0.47 |
Net Change from Assets/Liabilities | NA | -1.68 | -0.53 | -2.12 | -1.06 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 1.21 | 3.26 | 1.43 | 0.99 |
Net Cash From Operating Activities | NA | -8.44 | -34.24 | -26.82 | -18.01 |
Property & Equipment | NA | -0.01 | -0.28 | -0.25 | -0.15 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.01 | -0.28 | -0.25 | -0.15 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.41 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | -1.67 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | -0.12 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -1.26 | -0.12 | 0.00 | 0.00 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -9.70 | -34.65 | -27.08 | -18.16 |
Cash at Beginning of Period | NA | 35.68 | 70.32 | 70.32 | 70.32 |
Cash at End of Period | NA | 25.98 | 35.68 | 43.25 | 52.16 |
Diluted Net EPS | NA | -0.28 | -0.39 | -0.29 | -0.33 |